These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12899572)

  • 1. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Harandi AM; Czerkinsky C
    Expert Rev Vaccines; 2003 Apr; 2(2):205-17. PubMed ID: 12899572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
    Holmgren J; Czerkinsky C; Eriksson K; Mharandi A
    Vaccine; 2003 Jun; 21 Suppl 2():S89-95. PubMed ID: 12763689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in mucosal vaccines and adjuvants.
    Eriksson K; Holmgren J
    Curr Opin Immunol; 2002 Oct; 14(5):666-72. PubMed ID: 12183170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
    McCluskie MJ; Weeratna RD; Clements JD; Davis HL
    Vaccine; 2001 Jun; 19(27):3759-68. PubMed ID: 11395211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
    Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier.
    Lebens M; Holmgren J
    Dev Biol Stand; 1994; 82():215-27. PubMed ID: 7958476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.
    Pizza M; Giuliani MM; Fontana MR; Monaci E; Douce G; Dougan G; Mills KH; Rappuoli R; Del Giudice G
    Vaccine; 2001 Mar; 19(17-19):2534-41. PubMed ID: 11257389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of adjuvants in the development of mucosal vaccines.
    Vajdy M; Singh M
    Expert Opin Biol Ther; 2005 Jul; 5(7):953-65. PubMed ID: 16018740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
    Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
    Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.
    Bagley KC; Abdelwahab SF; Tuskan RG; Lewis GK
    Infect Immun; 2003 Dec; 71(12):6850-6. PubMed ID: 14638772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal delivery of vaccines.
    Del Giudice G; Pizza M; Rappuoli R
    Methods; 1999 Sep; 19(1):148-55. PubMed ID: 10525451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholera-like enterotoxins and Regulatory T cells.
    Basset C; Thiam F; Martino CD; Holton J; Clements JD; Kohli E
    Toxins (Basel); 2010 Jul; 2(7):1774-95. PubMed ID: 22069660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin.
    de Haan L; Verweij W; Agsteribbe E; Wilschut J
    Immunol Cell Biol; 1998 Jun; 76(3):270-9. PubMed ID: 9682971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.
    Arrington J; Braun RP; Dong L; Fuller DH; Macklin MD; Umlauf SW; Wagner SJ; Wu MS; Payne LG; Haynes JR
    J Virol; 2002 May; 76(9):4536-46. PubMed ID: 11932419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.
    Richards CM; Aman AT; Hirst TR; Hill TJ; Williams NA
    J Virol; 2001 Feb; 75(4):1664-71. PubMed ID: 11160664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in cross-protection in rats immunized with the B subunits of cholera toxin and Escherichia coli heat-labile toxin.
    Klipstein FA; Engert RF; Clements JD; Houghten RA
    Infect Immun; 1984 Mar; 43(3):811-6. PubMed ID: 6365784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines.
    Peppoloni S; Ruggiero P; Contorni M; Morandi M; Pizza M; Rappuoli R; Podda A; Del Giudice G
    Expert Rev Vaccines; 2003 Apr; 2(2):285-93. PubMed ID: 12899578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
    Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
    J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.